Omalizumab achieved a median drug survival of 3.1 years in chronic urticaria, and patients most often stopped the biologic because their disease was well controlled — not because of adverse events. Those findings come from a systematic review and meta-analysis of eight observational studies published September 9, 2026, in JAMA Dermatology (Altayf A, et al.; doi:10.1001/jamadermatol.2026.2043).

The analysis pooled 4,516 patients with chronic urticaria across the eight studies, which reported time-to-discontinuation or drug survival outcomes with omalizumab. Investigators searched PubMed, Embase, and Web of Science. Primary outcomes were overall drug survival and reasons for discontinuation; predictors of discontinuation served as secondary outcomes.

Omalizumab carries a recommendation as second-line therapy for chronic urticaria, yet the study authors pointed to a persistent gap: clinical evidence "regarding long-term drug survival and determinants of discontinuation" has been lacking.

What did the survival data show?

At 7 years of follow-up, the mean treatment duration was 3.75 years. The 3.1-year median drug survival signals durable real-world persistence for a therapy used long term in refractory disease.

Phenotype mattered. Patients with chronic inducible urticaria — with or without concurrent chronic spontaneous urticaria — tended toward longer drug survival than patients with chronic spontaneous urticaria alone.

Adverse-event-driven discontinuation was uncommon across the pooled cohort. Early discontinuation occurred most often because the disease was well controlled.

How did comorbidities shape discontinuation?

Reasons for stopping omalizumab diverged by comorbidity profile:

• Autoimmune comorbidities, mainly thyroid-related, carried a higher risk of discontinuation due to lack of efficacy.
• Atopic comorbidities carried a higher risk of discontinuation due to well-controlled disease.

The authors concluded that discontinuation was "more often due to disease control than adverse events."

Because "distinct comorbidity profiles" drove "divergent discontinuation patterns," the authors argued the findings highlight "the need for immune endotyping in long-term management" of chronic urticaria.

For clinicians, the practical implication is direct: an autoimmune phenotype — particularly with thyroid involvement — flags a patient at higher risk of losing response, while an atopic phenotype flags a patient more likely to achieve sustained control sufficient to stop therapy. Immune endotyping before and during treatment may help tailor follow-up intervals and retreatment decisions as longer-acting urticaria biologics and broader pipelines continue to mature.